Beijing New Oriental Star Petrochemical Engineering Co Ltd (002755) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing New Oriental Star Petrochemical Engineering Co Ltd (002755) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥187.71 Million ≈ $27.47 Million USD) by net assets (CN¥3.27 Billion ≈ $478.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Beijing New Oriental Star Petrochemical to measure how much of total assets are equity-financed.
Beijing New Oriental Star Petrochemical Engineering Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Beijing New Oriental Star Petrochemical Engineering Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 002755 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Beijing New Oriental Star Petrochemical Engineering Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing New Oriental Star Petrochemical Engineering Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G2 Goldfields Inc.
TO:GTWO
|
-0.003x |
|
Banpu Public Company Limited
BK:BANPU
|
0.016x |
|
Fagron NV
BR:FAGR
|
0.167x |
|
Sonida Senior Living Inc
NYSE:SNDA
|
-0.007x |
|
RLX Technology Inc
NYSE:RLX
|
0.022x |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
0.001x |
|
Cimpress plc
F:3UF
|
0.036x |
|
CBIZ Inc
NYSE:CBZ
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Beijing New Oriental Star Petrochemical Engineering Co Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Beijing New Oriental Star Petrochemical Engineering Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Beijing New Oriental Star Petrochemical (002755) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.14 Billion ≈ $459.81 Million |
CN¥411.36 Million ≈ $60.19 Million |
0.131x | +1583.47% |
| 2023-12-31 | CN¥3.01 Billion ≈ $440.56 Million |
CN¥-26.57 Million ≈ $-3.89 Million |
-0.009x | +49.65% |
| 2022-12-31 | CN¥3.01 Billion ≈ $440.95 Million |
CN¥-52.81 Million ≈ $-7.73 Million |
-0.018x | -109.96% |
| 2021-12-31 | CN¥3.23 Billion ≈ $472.29 Million |
CN¥567.71 Million ≈ $83.07 Million |
0.176x | -8.07% |
| 2020-12-31 | CN¥3.03 Billion ≈ $443.85 Million |
CN¥580.38 Million ≈ $84.93 Million |
0.191x | -9.93% |
| 2019-12-31 | CN¥2.52 Billion ≈ $368.25 Million |
CN¥534.62 Million ≈ $78.23 Million |
0.212x | -21.33% |
| 2018-12-31 | CN¥1.84 Billion ≈ $269.39 Million |
CN¥497.16 Million ≈ $72.75 Million |
0.270x | +414.08% |
| 2017-12-31 | CN¥585.03 Million ≈ $85.61 Million |
CN¥-50.30 Million ≈ $-7.36 Million |
-0.086x | -361.81% |
| 2016-12-31 | CN¥509.40 Million ≈ $74.54 Million |
CN¥16.73 Million ≈ $2.45 Million |
0.033x | +2179.89% |
| 2015-12-31 | CN¥508.35 Million ≈ $74.39 Million |
CN¥-802.68K ≈ $-117.46K |
-0.002x | +98.51% |
| 2014-12-31 | CN¥333.61 Million ≈ $48.82 Million |
CN¥-35.30 Million ≈ $-5.17 Million |
-0.106x | -143.79% |
| 2013-12-31 | CN¥307.51 Million ≈ $45.00 Million |
CN¥-13.35 Million ≈ $-1.95 Million |
-0.043x | -110.74% |
| 2012-12-31 | CN¥263.39 Million ≈ $38.54 Million |
CN¥106.47 Million ≈ $15.58 Million |
0.404x | +160.84% |
| 2011-12-31 | CN¥214.83 Million ≈ $31.44 Million |
CN¥33.29 Million ≈ $4.87 Million |
0.155x | -- |
About Beijing New Oriental Star Petrochemical Engineering Co Ltd
Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in oncology, antibiotic, and other areas. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 2003 and is bas… Read more